Contents
Definition
An anchor investor is a category of Qualified Institutional Buyer (QIB) that subscribes to and receives allotment of shares in an IPO or FPO one working day before the subscription opens, at the final issue price. The mechanism is governed by SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 (ICDR 2018), Chapter V, Regulation 30 and Schedule XIII. The anchor investor framework was introduced in India in 2009 to improve IPO market confidence: large institutional commitments at issue price before public subscription serve as a price-discovery signal and underpin demand visibility for the issuer and lead managers. Anchor investors must be QIBs applying for a minimum allotment of ₹10 crore. The maximum allocation to anchor investors is 60% of the QIB portion (which is typically 50% of net offer to public in a book-built issue), implying up to 30% of the total issue size can be allocated to anchors.
How it is structured
Under SEBI ICDR 2018 and amendments (including SEBI/HO/CFD/DIL1/CIR/P/2022/62 effective 2022 amending lock-in periods):
- Application timeline: Anchor investors apply one working day before the IPO subscription opens. Allotment is confirmed by the issuer and BRLM (Book Running Lead Manager) the same day.
- Price: At final issue price (the upper end of the price band or the discovered price). Anchors cannot pay less than other QIBs.
- Lock-in — post-2022 phased structure: For issues opening on/after 1 April 2022: 50% of anchor allocation locked-in for 90 days; remaining 50% locked-in for 30 days. Prior to 2022, all anchor shares were locked-in for 30 days uniformly.
- Allotment limits: No single anchor investor may receive more than 5% of the anchor portion from domestic mutual funds; for other anchors, up to 1/5th of anchor portion per investor.
- Domestic vs foreign: Both FPIs and domestic institutional investors (MFs, insurance, pension funds) can be anchor investors.
What investors should look at
Factual considerations regarding anchor investor disclosures:
- Anchor list quality: SEBI mandates disclosure of anchor investor names, allocation amounts, and price in the Red Herring Prospectus (RHP) addendum. Investors can review the calibre and diversity of anchor participants — domestic MFs, insurance companies, sovereign funds, FPIs — as part of IPO due diligence.
- Lock-in expiry dates: The 30-day and 90-day lock-in expiry (post-2022) creates potential selling pressure events. Monitor these dates; the first 30-day expiry typically coincides with the first month post-listing.
- Anchor allocation ≠ performance guarantee: Strong anchor subscription reflects institutional conviction at issue price but does not guarantee post-listing performance. Anchors may sell at lock-in expiry if the stock has appreciated beyond their target.
- Concentration check: Anchor portions dominated by a single large investor (e.g., one FPI with maximum allowable allocation) may indicate limited breadth of institutional interest.
Worked example
In Mankind Pharma's IPO (May 2023), the anchor investor book was subscribed at ₹1,080 per share (upper price band). Anchor investors included domestic MFs such as HDFC MF, SBI MF, Nippon India MF, and select FPIs — totalling approximately ₹900 crore across the anchor portion. The disclosure was made public in the RHP addendum one day before subscription opened. Post-2022 rules applied: 50% of each anchor's shares were locked for 30 days post-allotment, and the remaining 50% for 90 days. The 30-day lock-in expiry fell in late June 2023, creating a monitored event date for market observers tracking secondary selling pressure from anchor exits.
See also
- QIB / NII / RII — IPO Investor Categories
- IPO Allotment Process
- Grey Market Premium (GMP)
- IPO Dashboard
- Mankind Pharma IPO
Primary source
SEBI (ICDR) Regulations 2018, Regulation 30 and Schedule XIII; SEBI/HO/CFD/DIL1/CIR/P/2022/62 (28 Apr 2022) — anchor lock-in amendment. MintByte content is for informational purposes only and does not constitute investment advice. MintByte is registered with AMFI as ARN-314872 and with APMI as APRN-01658.